Purchased this stock at .85 cents on the 15th, based on an article on oct 10th, today news came out states: Regulatory Approval: The approval from China's National Medical Products Administration (NMPA) for the Phase 2b PALIZADE trial signifies regulatory confidence in the potential of zetomipzomib. Regulatory approvals are critical milestones in drug development,...
$KZR is a Biotech with 99 RS that is setting up. Focus list for next week. Look at how the indices are on the verge of breaking down and where this stock is. Its in a bull market of its own.
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various...
This stock has a recent increase in institutional transactions of 128%. With Inst. ownership of ~ 43%. Moving average price following looks prime too. Like i said before, Not a big penny stock guy... just an opportunity guy.
"KZR" is going up for the next coming weeks. It's definitely the moment to buy and hold this stock.
Please keep in mind not to take anything I say seriously, as this is of opinion basis and not face value. That being said, let us get to the analysis. I believe through the Fibonacci retracement, we can look at a short target of $5 for the next trend analysis goal of Kezar life sciences. Kezar had a huge decline in price over the past year, but the strong support...
Could make for a good swing trade to $5.35? NASDAQ:KZR
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616,...